[go: up one dir, main page]

ES2195819T3 - Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan. - Google Patents

Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan.

Info

Publication number
ES2195819T3
ES2195819T3 ES00111377T ES00111377T ES2195819T3 ES 2195819 T3 ES2195819 T3 ES 2195819T3 ES 00111377 T ES00111377 T ES 00111377T ES 00111377 T ES00111377 T ES 00111377T ES 2195819 T3 ES2195819 T3 ES 2195819T3
Authority
ES
Spain
Prior art keywords
chitosan
ofloxacino
watery
antibacterial
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00111377T
Other languages
English (en)
Inventor
Robert Gurny
Olivia Mireille Felt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Medidom SA
Original Assignee
Laboratoire Medidom SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom SA filed Critical Laboratoire Medidom SA
Application granted granted Critical
Publication of ES2195819T3 publication Critical patent/ES2195819T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Formulación oftálmica acuosa para el tratamiento y la prevención de infecciones, que contiene ofloxacino como principio activo y un chitosan con un peso molecular medio ponderado de 500.000 a 5.000.000 Daltons y un grado de desacetilación del 30 al 90 % como agente solubilizante de ofloxacino.
ES00111377T 2000-05-26 2000-05-26 Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan. Expired - Lifetime ES2195819T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00111377A EP1157688B1 (en) 2000-05-26 2000-05-26 Antibacterial aqueous ophthalmic formulations containing ofloxacin and chitosan

Publications (1)

Publication Number Publication Date
ES2195819T3 true ES2195819T3 (es) 2003-12-16

Family

ID=8168851

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00111377T Expired - Lifetime ES2195819T3 (es) 2000-05-26 2000-05-26 Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan.

Country Status (11)

Country Link
US (1) US6589999B2 (es)
EP (1) EP1157688B1 (es)
AT (1) ATE238767T1 (es)
BR (1) BR0102138B1 (es)
CA (1) CA2346631C (es)
CZ (1) CZ299195B6 (es)
DE (1) DE60002448T2 (es)
DK (1) DK1157688T3 (es)
ES (1) ES2195819T3 (es)
PL (1) PL201564B1 (es)
PT (1) PT1157688E (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716970B2 (en) 2000-04-21 2004-04-06 Adjuvant Pharmaceuticals, Llc Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
US7125967B2 (en) * 2003-10-08 2006-10-24 Adjuvant Pharmaceuticals, Llc Water-soluble chitosan having low endotoxin concentration and methods for making and using the same
US7125122B2 (en) * 2004-02-02 2006-10-24 Sharp Laboratories Of America, Inc. Projection system with corrective image transformation
US20060287278A1 (en) * 2005-06-21 2006-12-21 Zhenze Hu Method for improving water solubility of chitosan
CN100350978C (zh) * 2005-07-12 2007-11-28 何伟 可载药的降解型泪道栓子及其制备方法
FR3016882A1 (fr) 2014-01-30 2015-07-31 Sofradim Production Procede de preparation de chitosane a haut degre d’acetylation
CN108348516B (zh) * 2015-10-29 2021-02-12 特一华制药株式会社 外用剂
CN109846820B (zh) * 2019-04-09 2020-09-29 广东三蓝药业股份有限公司 一种氧氟沙星滴眼液及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675535A5 (es) * 1988-11-28 1990-10-15 Nestle Sa
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
ATE285751T1 (de) * 1998-11-20 2005-01-15 Medidom Lab Wässrige ophthalmische formulierungen mit chitosan

Also Published As

Publication number Publication date
CZ299195B6 (cs) 2008-05-14
EP1157688A1 (en) 2001-11-28
ATE238767T1 (de) 2003-05-15
PT1157688E (pt) 2003-08-29
DE60002448T2 (de) 2004-03-25
EP1157688B1 (en) 2003-05-02
CZ20011784A3 (cs) 2002-02-13
BR0102138B1 (pt) 2013-03-19
US6589999B2 (en) 2003-07-08
PL201564B1 (pl) 2009-04-30
PL347735A1 (en) 2001-12-03
BR0102138A (pt) 2002-03-12
CA2346631A1 (en) 2001-11-26
DE60002448D1 (de) 2003-06-05
US20020002148A1 (en) 2002-01-03
DK1157688T3 (da) 2003-08-25
CA2346631C (en) 2008-12-02

Similar Documents

Publication Publication Date Title
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
EP1364643A4 (en) COMPOSITION WITH IMPROVED SOLUBILITY OR ORAL ABSORBIBILITY
MY125356A (en) Moxifloxacin/sodium chloride formulation
WO1999032158A3 (en) Aminobiguanides to disinfect contact lenses and preserve pharmaceutical compositions
PT90124A (pt) Processo para a preparacao de composicoes farmaceuticas de piroxicamo em solucoes aquosas
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
GR3032116T3 (en) A method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
HRP20010878B1 (en) Ziprasidone suspension
ES2195819T3 (es) Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan.
WO2003082926A3 (en) Antimicrobial polymer conjugates
DK1128809T3 (da) Vandige oftalmiske formuleringer omfattende chitosan
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR0210632A (pt) Tratamento de doença parasìtica
SE0001916D0 (sv) Novel formulation
DE50206505D1 (de) Desinfektionsmittel für absauganlagen im medizinischen bereich
WO2001097774A3 (de) Neue pharmazeutische zusammensetzung zur topischen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen
WO2001066097A3 (de) Wirkstoff gegen keime der gattung pseudomonas
WO2002002087A3 (de) Anthelmintika zur verhinderung von parasitären infektionen bei menschen und tieren ii
BR0108458B1 (pt) biopolìmero sob forma seca, dispersìvel e com hidratação rápida, utilização do mesmo, e, formulação.
WO2002002089A3 (de) Anthelminthika zur verhinderung von parasitären infektionen bei mensch und tier iv
CA2468033A1 (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
AU4166599A (en) Glucopyranose derivatives and preventives and/or remedies for hiv infection containing the same as the active ingredient
AU6908801A (en) Anthelminthic agents for the prevention of parasitic infections in humans and animals
WO2002002088A3 (de) Anthelminthika zur verhinderung von parasitären infektionen bei mensch und tier iii
RU99102322A (ru) Средство для подавления роста сульфат-восстанавливающих бактерий